Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMT-28 in primary mitochondrial disease with myopathy and/or cardiomyopathy and inflammation
NL-OMON60153Phase 2Completed
- Sponsor
- OMEICOS Therapeutics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OMT-28 in Mitochondriopathy, sponsored by OMEICOS Therapeutics. Started May 2024; status: completed.
02
Drugs
OMT-28
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON60153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60153.